Thrombus - 2005


A review of Buerger’s disease
Tony Todd
pp 1-3
Buerger’s disease was first described by the German physician, von Winiwarter1 in 1879, although it is named after Leo Buerger, Professor of urological surgery at the Mount Sinai Hospital in New York. In 19082 he published a detailed description of the disease and the pathological findings in 11 limbs amputated from young Jewish men. However, it was not until the late 1960s that the disease was universally accepted as a distinct clinical condition.
Comment: Very high D-dimers – what do they mean?
Peter Rose
pp 2-2
D-dimer assays are commonly used as part of the screening assessment for patients with suspected venous thromboembolic disease (VTE). The assay results are best interpreted in conjunction with a formal clinical probability score. As D-dimer levels may be raised in many acute medical conditions, the clinical consensus is that the only useful D-dimer assay is a negative result that has a high negative predictive value for VTE. Further concerns about the value of D-dimer assays have been recently raised, particularly in the management of elderly patients. As D-dimer levels increase with age and the elderly often have multiple pre-existing co-morbidity, it may be particularly difficult to interpret results in this patient group.
Bleeding risk of LMWHs used at therapeutic dose in the elderly
Isabelle Gouin-Thibault, Virginie Siguret and Eric Pautas
pp 4-6
The incidence of acute thromboembolic events increases with age. The number of elderly patients treated with low molecular weight heparins (LMWHs) at therapeutic dose is rising steadily as the population ages. Meta-analysis of randomised trials has shown that LMWHs given at a bodyweight-adjusted dose, once or twice daily, are at least as safe and effective as unfractionated heparin (UFH) in the initial treatment of deep vein thrombosis (DVT), non-lifethreatening pulmonary embolism (PE), and for the management of patients with acute coronary syndromes (ACS).
Antenatal venous thromboembolism
Jenny Voke
pp 7-9
In pregnancy, acute venous thromboembolism (VTE), including deep vein thrombosis (DVT), pulmonary embolism (PE) and rarer events, such as cerebral venous thrombosis (CVT), pose different, less familiar problems from those encountered in non-pregnant patients, and require specialist input to ensure the safety of both mother and baby. Many hospitals encounter fewer than five antenatal patients with VTE per year; therefore, the management of these patients is challenging, due to limited local experience and the lack of evidence on which to base guidelines.
The outpatient management of pulmonary embolism
Christopher Davies
pp 10-11
Pulmonary embolism (PE) is a potentially fatal disease requiring early and accurate management and is a frequent reason for assessment in hospital.1,2 The principal treatment for confirmed PE has been the administration of heparin, followed by oral anticoagulation, such as warfarin. This treatment is still predominantly administered, while patients are admitted as inpatients due to the perceived risk of mortality from PE.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)

Site Map | company profile | contact us | testimonials | current vacancies | © 2011 - 2024 Your Company Name